Integra LifeSciences (NASDAQ:IART) Upgraded to Hold at BMO Capital Markets

BMO Capital Markets upgraded shares of Integra LifeSciences (NASDAQ:IART) to a hold rating in a research report report published on Wednesday,Zacks.com reports.

IART has been the topic of a number of other research reports. Citigroup reissued a “neutral” rating and set a $19.00 price objective (up from $16.00) on shares of Integra LifeSciences in a research report on Wednesday. Wells Fargo & Company raised their price objective on Integra LifeSciences from $12.00 to $15.00 and gave the company an “equal weight” rating in a research note on Wednesday, May 6th. Weiss Ratings upgraded Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, May 13th. Argus raised Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 target price on the stock in a research report on Thursday, June 18th. Finally, Truist Financial reduced their price target on shares of Integra LifeSciences from $13.00 to $12.00 and set a “hold” rating for the company in a research report on Wednesday, April 15th. One analyst has rated the stock with a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Reduce” and an average price target of $17.17.

Integra LifeSciences Price Performance

Shares of IART opened at $18.39 on Wednesday. The firm has a market cap of $1.43 billion, a PE ratio of -2.85, a price-to-earnings-growth ratio of 1.20 and a beta of 1.22. Integra LifeSciences has a 52-week low of $8.70 and a 52-week high of $18.92. The business’s 50 day moving average price is $16.15 and its two-hundred day moving average price is $12.81. The company has a debt-to-equity ratio of 1.75, a quick ratio of 1.95 and a current ratio of 3.38.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings data on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.13. The company had revenue of $391.92 million during the quarter, compared to analyst estimates of $381.81 million. Integra LifeSciences had a negative net margin of 30.15% and a positive return on equity of 17.42%. Integra LifeSciences’s revenue for the quarter was up 2.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.41 EPS. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. On average, equities analysts anticipate that Integra LifeSciences will post 2.45 EPS for the current year.

Institutional Investors Weigh In On Integra LifeSciences

Institutional investors have recently bought and sold shares of the stock. Rubric Capital Management LP lifted its stake in Integra LifeSciences by 1.3% during the 4th quarter. Rubric Capital Management LP now owns 7,753,934 shares of the life sciences company’s stock valued at $96,304,000 after acquiring an additional 100,000 shares in the last quarter. Paradigm Capital Management Inc. NY grew its stake in shares of Integra LifeSciences by 50.6% in the 1st quarter. Paradigm Capital Management Inc. NY now owns 4,012,698 shares of the life sciences company’s stock worth $37,800,000 after acquiring an additional 1,347,700 shares in the last quarter. Invesco Ltd. grew its stake in shares of Integra LifeSciences by 0.9% in the 4th quarter. Invesco Ltd. now owns 3,522,839 shares of the life sciences company’s stock worth $43,754,000 after acquiring an additional 31,931 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Integra LifeSciences by 9.2% in the third quarter. Dimensional Fund Advisors LP now owns 3,184,726 shares of the life sciences company’s stock valued at $45,634,000 after purchasing an additional 267,134 shares during the last quarter. Finally, State Street Corp raised its holdings in shares of Integra LifeSciences by 0.8% in the fourth quarter. State Street Corp now owns 2,812,615 shares of the life sciences company’s stock valued at $34,933,000 after purchasing an additional 21,717 shares during the last quarter. Institutional investors own 84.78% of the company’s stock.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.